ホームMCPワークベンチSkills
ホームワークベンチ通知マイページ
llms.txt · MCPガイドプライバシーポリシー · 利用規約 · サポートv1.8.1
  1. ホーム
  2. /化合物

ガリウムトリニトラート

Gallium nitrate

HCID 61635
反応を作成
印刷
基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート
部分構造検索類似構造を探す

基本情報

CAS
13494-90-1
標準SMILES
O=[N+]([O-])[O-].O=[N+]([O-])[O-].O=[N+]([O-])[O-].[Ga+3]
InChIKey
CHPZKNULDCNCBW-UHFFFAOYSA-N
分子式
GaN3O9
平均分子量
255.74 g/mol
単同位体質量
254.88903

概要

Gallium nitrate appears as white crystals. (NTP, 1992)

名称と識別子

優先名称
Gallium nitrate
IUPAC
gallium trinitrate
現地名
ガリウムトリニトラート
英語名
GALLIUM NITRATE
分子式
GaH4NO3
分子量
135.76

名称と別名

Gallium nitrateGanite13494-90-1Nitric acid, gallium saltGallium nitrate anhydrousNSC-15200Gallium nitrate (anhydrous)Y2V2R4W9TQDTXSID0043923NSC 15200GALLIUM NITRATE (GA(NO3)3)Gallium Nitricum
名称をさらに表示
硝酸ガリウム(III)ガリウムトリニトラート三硝酸ガリウム硝酸ガリウム(III)(1:3)硝酸ガリウム(Ⅲ)n水和物硝酸ガリウム(III)N水和物, 99.9%硝酸ガリウム(III)N水和物硝酸ガリウム(III) solution, Ga 9-10% w/wGa(NO3)3nH2OGa(NO3)3?5H2OWln: ga N-o3*3galliumtrinitrateGallium(Ⅲ) nitrateGALLIUM (III) NITRATENitricacid,galliumsalt
RefChem:634096DTXCID8023923236-815-5135886-70-3Gallium nitrate nonahydrateVRA0C6810NGALLIUM(III) NITRATEMFCD00011016

データベース識別子

CAS
13494-90-1
PubChem CID
61635
DTXSID
DTXSID0043923
ChEMBL
CHEMBL1200983
ChEBI
CHEBI:231505
UNII
Y2V2R4W9TQ
EC Number
236-815-5

物性

構造計算による物性

極性表面積
189 Ų
水素結合供与体数
0
水素結合受容体数
9
回転可能結合数
0
重原子数
13
形式電荷
0
複雑度
18.8

実験および物理化学的性質

SolubilityVery soluble (NTP, 1992)
Human Drugs · 2 件

FDA approved drugs -> Active ingredient

FDA approved drugs -> Active ingredient

Melting Point230 °F (decomposes) (NTP, 1992)
Physical DescriptionGallium nitrate appears as white crystals. (NTP, 1992)

物理化学的性質

融点
110 °C · 110°C (dec.)
溶解性
2 O, · soluble in H2O, ethanol, ethyl ether
外見
液体
色
white crystals, crystalline powder
水溶解度
水に溶けます。
InChI
1S/Ga.3NO3/c;3*2-1(3)4/q+3;3*-1
InChIKey
CHPZKNULDCNCBW-UHFFFAOYSA-N
SMILES
[Ga+3].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O
EPAの化学物質情報
Gallium nitrate (13494-90-1)
化学的性質 · 1 件

安全と法規制

安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。

GHS分類

GHS Classification · 4 件

Danger

H272 (100%): May intensify fire; oxidizer [Danger Oxidizing liquids; Oxidizing solids]

P210, P220, P260, P261, P264, P264+P265, P271, P280, P301+P330+P331, P302+P352, P302+P361+P354, P304+P340, P305+P351+P338, P305+P354+P338, P316, P319, P321, P332+P317, P337+P317, P362+P364, P363, P370+P378, P403+P233, P405, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 10 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

危険有害性情報

Regulatory InformationChemical: Nitric acid, gallium salt
DOT LabelOxidizer
Fire HazardsFlash point data for this chemical are not available, but it is probably combustible. (NTP, 1992)
Health HazardsSYMPTOMS: Symptoms of exposure to this compound include nausea, vomiting, renal function depression, proteinuria, normocytic anemia and thrombocytopenia.
Reactive GroupNitrate and Nitrite Compounds, Inorganic
Reactivity AlertsStrong Oxidizing Agent
Reactivity Profile · 1 件

Oxidizing agents, such as GALLIUM NITRATE, can react with reducing agents to generate heat and products that may be gaseous (causing pressurization of closed containers). The products may themselves be capable of further reactions (such as combustion in the air). The chemical reduction of materials in this group can be rapid or even explosive, but often requires initiation (heat, spark, catalyst, addition of a solvent). Explosive mixtures of inorganic oxidizing agents with reducing agents often persist unchanged for long periods if initiation is prevented. Such systems are typically mixtures of solids, but may involve any combination of physical states. Some inorganic oxidizing agents are salts of metals that are soluble in water; dissolution dilutes but does not nullify the oxidizing power of such materials. Organic compounds, in general, have some reducing power and can in principle react with compounds in this class. Actual reactivity varies greatly with the identity of the organic compound. Inorganic oxidizing agents can react violently with active metals, cyanides, esters, and thiocyanates.

化学と産業

薬理情報

Protein BindingNo information is available.
Pharmacodynamics · 1 件

Gallium nitrate produces a hypocalcemic effect by inhibiting calcium resorption from bone, possibly blocking osteoclast activity and reducing increased bone turnover. Preclinical studies demonstrated that gallium dose-dependently accumulates in areas of high bone turnover, where it is incorporated into hydroxyapatite, making it less susceptible to dissolution and osteoclast-mediated resorption. No cytotoxic effects were observed on bone cells in drug-treated animals. Gallium nitrate exhibits antitumour activity, which is reported to be unrelated to the physiological mechanism involved in its bone turnover effects. Anti-inflammatory and immunosuppressant effects have also been documented.

Mechanism of Action · 1 件

A high incidence of hypercalcemia is often observed in patients with non-small cell lung cancer, breast cancer, multiple myeloma, kidney cancer, and cancer of head and neck. Hypercalcemia of malignancy seems to result from an imbalance between the net resorption of bone and urinary excretion of calcium. Patients with extensive osteolytic bone metastases frequently develop hypercalcemia. Although _in vitro_ and animal studies have been performed to investigate the mechanism of action of gallium nitrate, the precise mechanism for inhibiting calcium resorption has not been determined. Gallium, the active component that exerts the physiological effects of gallium nitrate, may induce physicochemical changes in the bone matrix to promote hydroxyapatite crystallization and attenuate mineral dissolution. Gallium may also decrease acid secretion by osteoclasts and modulate the synthesis of osteocalcin, an osteoblast-specific bone matrix protein that triggers bone resorption. Osteoclast morphology or viability is not reported to be affected. Gallium nitrate may modulate inflammation. _In vitro_, it was shown to block the production of inflammatory cytokines, such as interleukin-1 (IL-1) beta, by macrophage-like cells. Gallium nitrate also dose-dependently inhibited matrix metalloproteinase activity promoted by tissue plasminogen activator (tPA).

Biological Half-Life · 1 件

In phase I studies involving cancer patients who received a short-term intravenous infusion of single doses ranging from 300 to 900 mg/m<sup>2</sup>, a biphasic curve was observed. Gallium nitrate exhibited a mean initial (distribution phase) half-life of 1 to 1.5 hours and a terminal (elimination phase) half-lives of 25 to 30 hours.

関連反応

3 件
反応記録を作成
HRID 871824 の反応式
HRID 871824生成物としてuspto-grants-2015_03
HRID 1264442 の反応式
HRID 1264442生成物としてuspto-grants-2003_04
HRID 1288800 の反応式
HRID 1288800反応物としてuspto-grants-1998_05

化合物ノート

このページの内容基本情報概要名称と識別子物性安全と法規制化学と産業関連反応化合物ノート

化学的特性The structural formula of gallium nitrate is Ga(NO3)3. Gallium nitrate is an anhydrate salt that is very soluble in water and soluble in 95% ethanol. It is stable in commonly used intravenous fluids for 14 days at room temperature and at 5 ℃, and physically compatible for injection with selected drug products, with the exception of diazepam injection.This chemical is an oxidizer, and is probably combustible

Air and Water ReactionsDeliquescent. Water soluble.
Hazard Classes and CategoriesOx. Sol. 2 (100%)

安全と保護具

Fire FightingFires involving this material can be controlled with a dry chemical, carbon dioxide or Halon extinguisher. (NTP, 1992)
First Aid · 1 件

EYES: First check the victim for contact lenses and remove if present. Flush victim's eyes with water or normal saline solution for 20 to 30 minutes while simultaneously calling a hospital or poison control center. Do not put any ointments, oils, or medication in the victim's eyes without specific instructions from a physician. IMMEDIATELY transport the victim after flushing eyes to a hospital even if no symptoms (such as redness or irritation) develop.

Nonfire Spill Response · 1 件

SMALL SPILLS AND LEAKAGE: If you spill this chemical, you should dampen the solid spill material with water, then transfer the dampened material to a suitable container. Use absorbent paper dampened with water to pick up any remaining material. Seal your contaminated clothing and the absorbent paper in a vapor-tight plastic bag for eventual disposal. Wash all contaminated surfaces with a soap and water solution. Do not reenter the contaminated area until the Safety Officer (or other responsible person) has verified that the area has been properly cleaned.

Isolation and EvacuationExcerpt from ERG Guide 140 [Oxidizers]:
Personal Protective Equipment (PPE) · 1 件

RECOMMENDED RESPIRATOR: Where the neat test chemical is weighed and diluted, wear a NIOSH-approved half face respirator equipped with an organic vapor/acid gas cartridge (specific for organic vapors, HCl, acid gas and SO2) with a dust/mist filter. (NTP, 1992)

毒性情報

Drug Induced Liver Injury · 6 件

Drug Induced Liver Injury Rank (DILIrank 2.0)

Gallium nitrate

Ambiguous-DILI-concern

3

Adverse reactions

DOI:10.1016/j.drudis.2016.02.015

安全データ

wgk
WGK 3
tsca
TSCA listed
ridadr
1477
risk_code
8-36/37/38
safety_code
17-26-36/37/39
hazard_class
5.1
packing_group
III
Hazard Classifications
Eye Irrit. 2Ox. Liq. 2Skin Irrit. 2
ストレージクラス
5.1B - Oxidizing hazardous materials
Metabolism/MetabolitesGallium nitrate is not metabolized either by the liver or the kidney.
FDA Pharmacological Classification · 5 件

Y2V2R4W9TQ

GALLIUM NITRATE ANHYDROUS

Physiologic Effects [PE] - Bone Resorption Inhibition

Established Pharmacologic Class [EPC] - Calcium Resorption Inhibitor

Gallium nitrate anhydrous is a Calcium Resorption Inhibitor. The physiologic effect of gallium nitrate anhydrous is by means of Bone Resorption Inhibition.

MeSH Pharmacological Classification · 2 件

Substances that inhibit or prevent the proliferation of NEOPLASMS.

Hormones and molecules with calcium-regulating hormone-like actions that modulate OSTEOLYSIS and other extra-skeletal activities to maintain calcium homeostasis.

Absorption, Distribution and Excretion · 4 件

Gallium nitrate was infused at a daily dose of 200 mg/m2 for 5 (n=2) or 7 (n=10) consecutive days to 12 cancer patients. In most patients, mean steady-state plasma concentrations were reached after 18 to 24 hours of infusion. The average steady-state plasma levels of gallium observed among seven fully evaluable patients was between 1134 and 2399 ng/mL. In one patient who received daily infusion doses of 100, 150 and 200 mg/m2, the apparent steady-state levels of gallium did not increase proportionally with an increase in dose.

Gallium nitrate appears to be significantly excreted via the kidney. In phase I studies involving cancer patients who received a short-term intravenous infusion of single doses ranging from 300 to 900 mg/m<sup>2</sup>, about two-thirds of the administered dose was recovered in the urine in the first 24 hours post-dose.

In phase I studies involving cancer patients who received a short-term intravenous infusion of single doses ranging from 300 to 900 mg/m<sup>2</sup>, the mean volume of distribution of gallium was 1.27 L/kg.

In cancer patients who received a daily infusion of gallium nitrate at a dose of 200 mg/m<sup>2</sup> for five to seven consecutive days, the average plasma clearance of gallium was 0.15 L/hr/kg (range: 0.12 to 0.20 L/hr/kg).

用途と製造

General Manufacturing InformationNitric acid, gallium salt (3:1): ACTIVE
応用分野 · 5 件

用途分析におけるガリウムイオン供給源。

用途高純度金属化合物。

説明Gallium nitrate, initially developed as an anticancer agent, was introduced by Fujisawa as an orphan drug for the treatment of cancer-related hypercalcemia and bone metastases that do not respond to adequate hydration. The compound acts specifically on bone by inhibiting calcium resorption and also possibly by stimulating bone formation. Compared with calcitonin and etidronate, gallium nitrate is more potent and substantially longer acting. Other potential uses could be in the treatment of osteoporosis and Paget’s disease.

使用Gallium is the second metal ion with clinical activity used in cancer treatment. Gallium nitrate has demonstrated antitumor activity in a variety of murine tumor models, including Walker 256 carcinosarcoma, fibrosarcoma M-89, leukemia K-1964, adenocarcinoma 755, mammary carcinoma YMC, reticulum cell sarcoma A-RCS, lymphoma P1798, and osteosarcoma 124F. It was, however, ineffective in ascites, leukemias, plasma cell tumors, or Ehrlich carcinoma. In phase II evaluation studies, gallium nitrate has shown antitumor activity in patients with either refractory lymphomas or small-cell lung carcinomas or bladder cancer, with total objective response rates of 28% and 11%, respectively. This drug has displayed its strongest antineoplastic activity in the treatment of non-Hodgkin’s lymphoma and bladder cancer. In addition, according to two phase III comparative trials,thanks to an inhibitory effect on calcium reabsorption from bone, gallium nitrate is superior to alternative therapies in the treatment of hypercalcemia associated with malignancy and related disease states. Based on its clinical efficacy, gallium nitrate (Ganite ) was approved by the Food and Drug Administration (FDA) for the treatment of cancerassociated hypercalcemia.Apart from its ability to control hypercalcemia, gallium nitrate has been shown to inhibit bone turnover and decrease osteolysis in patients with multiple myeloma and in patients with bone metastases from a variety of different cancers.

一般的な説明White crystals.

上流・下流製品情報

上流原料

酸化ガリウム(Ⅲ)ガリウム